New hope for Tough-to-Treat breast cancer

NCT ID NCT04556773

Summary

This early-stage study is testing whether combining an existing breast cancer drug (trastuzumab deruxtecan) with other cancer therapies is safe and effective for patients with advanced HER2-low breast cancer. It involves 138 adults whose cancer has spread and who have tried other treatments. The main goal is to find the safest and most effective dose combinations.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Commack, New York, 11725, United States

  • Research Site

    Harrison, New York, 10604, United States

  • Research Site

    New York, New York, 10029, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Uniondale, New York, 11553, United States

  • Research Site

    Chapel Hill, North Carolina, 27514, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Germantown, Tennessee, 38138, United States

  • Research Site

    Fort Worth, Texas, 76104, United States

  • Research Site

    East Melbourne, 3002, Australia

  • Research Site

    Westmead, 2145, Australia

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Ottignies, 1340, Belgium

  • Research Site

    Goiânia, 74605-070, Brazil

  • Research Site

    Porto Alegre, 90035-003, Brazil

  • Research Site

    Porto Alegre, 90110-270, Brazil

  • Research Site

    São Paulo, 03102-002, Brazil

  • Research Site

    São Paulo, 04543-000, Brazil

  • Research Site

    Kelowna, British Columbia, V1Y 5L3, Canada

  • Research Site

    Québec, Quebec, G1J 1Z4, Canada

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Monterrey, 64710, Mexico

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 143442, Russia

  • Research Site

    Saint Petersburg, 199226, Russia

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Kaohsiung City, 82445, Taiwan

  • Research Site

    Taichung, 40443, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taipei, 11217, Taiwan

  • Research Site

    Taipei, 114, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan District, 333, Taiwan

Conditions

Explore the condition pages connected to this study.